Multimeric-001: BiondVax's universal flu vaccine. Interview by Duc Le.
Dr Tamar Ben-Yedidia has more than 15 years of experience in the field of immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd (BTG; Rehovot, Israel), working on the development of a recombinant hepatitis B vaccine. She joined the Weizmann Institute of Science (Rehovot, Israel) in 1994 and, under the auspices of Professor Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens, focusing on influenza. Dr Ben-Yedidia received her PhD from the Weizmann Institute after completion of her doctoral thesis entitled 'A Peptide-Based Vaccine Against Influenza'. She continued this work when she left the Weizmann Institute in 2005 to join BiondVax (Ness Ziona, Israel). She was involved in two European Consortium projects related to the evaluation of different approaches for vaccination in which leading laboratories in the field participated. She is often invited to address conferences around the world and has published around 20 refereed articles and invited reviews in various renowned scientific journals. In this interview, Dr Tamar Ben-Yedidia speaks to Commissioning Editor Duc Le.
Ben-Yedidia
Tamar
T
D035843:Biomedical Research / Q000639:trends; D002986:Clinical Trials as Topic; D017124:Conserved Sequence; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D007557:Israel; D009975:Orthomyxoviridae / Q000235:genetics*; D022223:Vaccines, Subunit / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
D007252:Influenza Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic